Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-HN and SEQ-HN tipifarnib study in HRAS-mutant head and neck squamous cell carcinoma
NL-OMON55489Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tipifarnib in head and neck squamous cell carcinoma (HNSCC) (2 cohorts), sponsored by Kura Oncology. Primary endpoint: Objective response rate. Started Oct 2019; status: completed.
02
Drugs
tipifarnib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON55489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55489.